Navigation Links
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
Date:3/18/2008

MONTREAL, March 18 /PRNewswire/ - Aegera Therapeutics announced today the initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in development for the treatment of painful diabetic neuropathy. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.

Aegera completed a comprehensive pre-clinical development program on AEG33773, culminating in regulatory clearance from Health Canada and treatment of a first patient, in less than 12 months.

"We are extremely excited about the potential for AEG33773 to treat painful diabetic neuropathy and to expand to other pain and neuropathy indications, based on our extensive preclinical experience with this family of compounds in multiple models of pain and neuropathy," commented Dr. Jon Durkin, Vice-President Research and Preclinical Development at Aegera.

"This important milestone was achieved in record time, as the Aegera team has successfully filed regulatory applications for two potential blockbuster compounds, AEG33773 and AEG40826, in the last three months while initiating multiple Phase 2 trials for our lead program AEG35156. Aegera now has four unique programs in clinical development and is poised to deliver significant clinical data over the next 12-18 months" added Dr. Michael J. Berendt, Aegera's President and CEO.

About AEG33773

AEG33773 was developed as an orally bioavailable small molecule compound which provides acute pain relief in preclinical models of neuropathic and inflammatory pain. In addition, AEG33773's unique mechanism of action has demonstrated excellent in vivo activity in models of diabetic neuropathy with respect to its ability to not only prevent, but also to reverse established neuropathies.

About Aegera Therapeutics Inc.

Aegera Therapeutic
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property development ... intellectual property, announced today that the Markman hearing ... the U.S. District Court for the Northern District ... rescheduled for November 10, 2014.  This hearing was ... Order setting the Markman date was received after ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 In ... cost-effective tools to address sales, training and consumer ... has developed innovative mobile applications to turn their ... the agency’s latest customized mobile app creations, are ... . , In partnership with Toyota, StudioPMG created ...
(Date:10/1/2014)... 01, 2014 The U.S. Department of ... Illinois University Edwardsville as part of the Trade Adjustment ... funding is co-administered by the Department of Labor and ... of Labor Thomas E. Perez and Secretary of Education ... job-driven training grants to nearly 270 colleges across the ...
(Date:9/30/2014)... is available in German . ... Universitt Mnchen (TUM) have demonstrated a new kind of ... that future computer chips could be based on three-dimensional ... main enabling technology of the semiconductor industry CMOS ... TUM researchers and collaborators at the University of Notre ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Digital Agency Studio PMG Launches New Case Studies on Website 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3
... 19, 2011 New Report Added in ... to 2020 - Programmable Logic Devices (PLD) and Application Specific ...   Published by  GBI Research . ... 2020 Programmable Logic Devices (PLD) and Application Specific Standard Product ...
... about how certain kinds of bacteria make energy and synthesize ... team of scientists led by Donald Bryant, the Ernest C. ... research professor in the Department of Chemistry and Biochemistry at ... the journal Science on 16 December 2011, is ...
... The efficiency of conventional solar cells could be ... of solar energy conversion led by chemist Xiaoyang Zhu ... and his team have discovered that it,s possible to ... of sunlight using an organic plastic semiconductor material. ...
Cached Biology Technology:ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 3ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 4Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 2Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 3Discovery of a 'dark state' could mean a brighter future for solar energy 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... On Monday, August 17th at 1:30PM in Hensill Hall 113, ... AAAS in San Francisco will get to learn about the ... minds in the field. The symposium is called Good ... the Public. (Online link: http://www.sou.edu/aaaspd/2009SANFRANCISCO/Symposia09.html#15 ). As science ...
... another piece to the mounting body of evidence that ... arrest, "passive ventilation" significantly increases survival rates, compared to ... in an online edition of Annals of Emergency Medicine, ... cardiac arrest outside a hospital setting and were resuscitated ...
... 12, 2009) Research published online in the journal ... are associated with a 2.5-fold reduction in risk for neural ... brain and spinal cord, and the two most common NTDs ... Disease Control (CDC), an estimated 3,000 pregnancies in the U.S. ...
Cached Biology News:Science communication to take the stage at annual AAAS meeting in San Francisco 2Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Essential nutrient found in eggs may help lower risk of neural tube defects 2Essential nutrient found in eggs may help lower risk of neural tube defects 3
... pp65 Antigenemia Immunofluorescence Assay (IFA) is intended ... protein pp65 of CMV in isolated peripheral ... Erythrocyte Lysis Buffer - (Catalog ... of buffered ammonium chloride. (NH4CL) Fixation ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... samples for freezing point determinations. Includes built-in printer, keypad, and software for ... RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: